• Contemporary ClinicContemporary Clinic
  • OTC GuideOTC Guide
  • Pharmacy Times
  • PTCEPTCE
  • Pharmacist Moms GroupPharmacist Moms Group
News
All News
FDA Updates
Press Releases
Media
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conferences
Conference Coverage
Conference Listing
Publications
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
Clinical
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Events
Upcoming Events
Upcoming Webinars
CE
Resources
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
logo
Spotlight
Community/RetailHospitalOncologyPharmacy TechnicianStudent
Clinical Role
Community/RetailHospitalOncologyPharmacy TechnicianSpecialty PharmacyStudent
Clinical
CoronavirusBrain HealthCardiovascular HealthDermatologyDiabetesFluHeart FailureHepatitis/MASHImmunizationMigrainePneumococcalVitamins and Supplements
Supplement Spotlight
October 2023 Pharmacy Technician Edition
All News
FDA Updates
Press Releases
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conference Coverage
Conference Listing
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Upcoming Events
Upcoming Webinars
CE
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
Advertisement

CLINICAL ROLE -

Community/Retail
| Hospital
| Oncology
| Pharmacy Technician
| Student

News

Article

February 5, 2025

Efruxifermin Demonstrates Potential in Treating Patients With MASH-Related Scarring or Cirrhosis

Author(s):

Gillian McGovern, Associate Editor

Key Takeaways

  • Efruxifermin mimics FGF21, targeting metabolic pathways to treat MASH by reversing liver scarring without worsening the condition.
  • Phase 3 SYNCHRONY trials evaluate efruxifermin's efficacy and safety in various MASH fibrosis stages, including pre-cirrhotic and cirrhotic conditions.
  • Phase 2b HARMONY trial showed significant fibrosis improvement with efruxifermin, achieving primary and secondary endpoints over 96 weeks.
  • Efruxifermin is generally well-tolerated, with mild gastrointestinal adverse events being the most common.
SHOW MORE

Efruxifermin is undergoing 3 phase 3 clinical trials to evaluate its safety, efficacy, and tolerability in metabolic dysfunction-associated steatohepatitis (MASH).

Liver with hepatitis/MASH -- Image credit: Rasi | stock.adobe.com

Image credit: Rasi | stock.adobe.com

In clinical trials, efruxifermin (Akero Therapeutics) demonstrated its ability to help patients who have metabolic dysfunction-associated steatohepatitis (MASH), a type of liver disease. Efruxifermin helped reverse scarring of the liver without worsening the patients’ condition.1

Efruxifermin is an experimental drug currently undergoing investigation for its efficacy in patients with severe scarring or cirrhosis because of MASH.1 It has been engineered to mimic the biological activity of a fibroblast growth factor 21 (FGF21), which can regulate multiple metabolic pathways and cellular processes. The investigational drug delivers sustained and balanced signaling through the FGF21 receptors in liver and adipose tissue, addressing all core drivers of disease progression, therefore, showing its potential to treat MASH.2,3

About the Trials

1. SYNCHRONY Histology

  • Trial Name: A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/​Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
  • ClinicalTrials.gov ID: NCT06215716
  • Sponsor: Akero Therapeutics, Inc
  • Completion Date (Estimated): November 2032

2. SYNCHRONY Real-World

  • Trial Name: A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/​Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/​Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
  • ClinicalTrials.gov ID: NCT06161571
  • Sponsor: Akero Therapeutics, Inc
  • Completion Date (Estimated): October 2026

3. SYNCHRONY Outcomes

  • Trial Name: A Study Evaluating Efruxifermin in Subjects with Compensated Cirrhosis Due to NASH/​MASH
  • ClinicalTrials.gov ID: NCT06528314
  • Sponsor: Akero Therapeutics, Inc
  • Completion Date (Estimated): October 2029

4. HARMONY

  • Trial Name: A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH) (Harmony)
  • ClinicalTrials.gov ID: NCT04767529
  • Sponsor: Akero Therapeutics, Inc
  • Completion Date (Estimated): May 2024

Currently, efruxifermin is being evaluated in the phase 3 SYNCHRONY program3, which consists of the 3 multicenter, randomized, double-blind, placebo-controlled clinical trials SYNCHRONY Histology (NCT06215716)4, SYNCHONY Real-World (NCT06161571)5, and SYNCHRONY Outcomes (NCT06528314)6. The trials are evaluating the following: the efficacy and safety of efruxifermin in patients with biopsy-confirmed pre-cirrhotic MASH, fibrosis stages 2 and 3 (SYNCHRONY Histology); the safety and tolerability of efruxifermin in patients with non-invasively diagnosed MASH or metabolic dysfunction-associated steatotic liver disease (MASLD), fibrosis stages 1 through 4 (SYNCHRONY Real-World); and efruxifermin for the treatment of compensated cirrhosis because of MASH, fibrosis stage 4 (SYNCHRONY Outcomes).3

In the randomized, double-blind, placebo-controlled phase 2b HARMONY trial (NCT04767529)7, investigators assessed the efficacy and safety of efruxifermin in patients with pre-cirrhotic MASH and stage 2 or 3 fibrosis. The trial met its primary end point and demonstrated that, compared with placebo, 28- and 50-mg doses of efruxifermin did not worsen patients’ MASH following 24 weeks of treatment (28 mg: 39%; 50 mg: 41%; and placebo: 20%).3,7

More patients experienced at least a 1-stage improvement in fibrosis without worsening of MASH in both dose groups (28 mg: 46%; 50 mg: 75%) compared with placebo (24%). Additionally, approximately 31% and 36% of patients in the 28-mg and 50-mg dose groups, respectively, experienced a 2-stage improvement in fibrosis without their disease worsening, which is over 10-fold compared with placebo (3%). Those who had stage 3 fibrosis were more likely to experience at least a 1-stage improvement in fibrosis when treated with efruxifermin (28 mg: 40%; 50 mg: 68%) compared with placebo (14%). The investigational treatment had also met secondary and exploratory end points through 96 weeks of treamtent.3

“Notwithstanding inherent limitations in making cross-trial comparisons, the statistically significant results for [at least] 1- and 2-stage fibrosis improvement and no worsening of MASH observed for 50 mg [of] efruxifermin at week 96 are the largest response rates reported publicly to date for these end points in any MASH population,” Stephen Harrison, MD, medical director of Pinnacle Clinical Research, said in a news release.8

Further, efruxifermin was shown to be generally well-tolerated. A total of 15 serious adverse events (AEs) were reported, and these were balanced across dose groups. In both dose groups, the most frequent AEs were grades 1 or 2 gastrointestinal complications (eg, diarrhea, nausea, and increased appetite), which were considered brief. Three participants treated with efruxifermin (28 mg: n = 2; 50 mg: n = 1) discontinued their treatment because of AEs between weeks 24 and 96. During the trial, no deaths were reported.8

REFERENCES
1. Reuters. Akero soars as drug shows it reverses scarring in liver disease patients. News release. January 27, 2025. Accessed January 28, 2025. https://www.reuters.com/business/healthcare-pharmaceuticals/akero-shares-double-after-preliminary-results-mid-stage-trial-liver-disease-drug-2025-01-27/
2. Akero Therapeutics. Efruxifermin (EFX). Accessed January 28, 2025. https://akerotx.com/efruxifermin/
3. Akero Therapeutics. Clinical Trials Overview. Accessed January 28, 2025. https://akerotx.com/clinical-trials/
4. A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/​Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis. ClinicalTrials.gov identifier: NCT06215716. Updated January 23, 2025. Accessed January 28, 2025. https://www.clinicaltrials.gov/study/NCT06215716
5. A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/​Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/​Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). ClinicalTrials.gov identifier: NCT06161571. Updated January 17 2025. Accessed January 28, 2025. https://www.clinicaltrials.gov/study/NCT06161571
6. A Study Evaluating Efruxifermin in Subjects with Compensated Cirrhosis Due to NASH/​MASH. ClinicalTrials.gov identifier: NCT06528314. Updated December 16, 2024. Accessed January 28, 2025. https://clinicaltrials.gov/study/NCT06528314
7. A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH) (Harmony). ClinicalTrials.gov identifier: NCT04767529. Updated April 21, 2023. Accessed January 28, 2025. https://clinicaltrials.gov/study/NCT04767529 
8. Akero Therapeutics. Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study. News release. March 4, 2024. Accessed January 28, 2025. https://ir.akerotx.com/news-releases/news-release-details/akero-therapeutics-reports-statistically-significant

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Tired scared retiree man holding chest with anginal symptoms, pallor and diaphoresis at home. Suffering male with cardiac origin pain, prexcordial pressure, arrhythmia risk, urgent medical attention - Image credit: DimaBerlin | stock.adobe.com
Image credit: Sebastian Kaulitzki | stock.adobe.com
Health and nutrition: the role of glp-1 in diabetes management with apple and syringe - Image credit: Thanayut | stock.adobe.com
Image credit: K KStock | stock.adobe.com
Image credit: komokvm | stock.adobe.com
Vial of Pneumococcal vaccine - Image credit: Bernard Chantal | stock.adobe.com
Vaccine vials used for Respiratory Syncytial Virus (RSV) with a syringe - Image credit:  Peter Hansen | stock.adobe.com
Related Content
Advertisement
raw vegetables with blood glucose meter, syringe, lancet and stethoscope on desk, diabetes healthy diet concept - Image credit: neirfy | stock.adobe.com
June 12th 2025

Study: How Individual Carbohydrate Responses Reveal Metabolic Health and Potential Biomarkers

Kennedy Ferruggia, Assistant Editor
Pharmacy Focus: Navigating Seasonal Allergies
May 28th 2025

Pharmacy Focus: Navigating Seasonal Allergies

Luke Halpern, Assistant Editor Derek Webb, PharmD
Wooden blocks spelling biosimilars -- Image credit: lexiconimages | stock.adobe.com
June 12th 2025

Understanding Biologics and Biosimilars Amid an Evolving Treatment Landscape

Gillian McGovern, Associate Editor
Pharmacists Can Be At the Forefront of Cardio-Kidney-Metabolic Management
May 6th 2025

Pharmacists Can Be At the Forefront of Cardio-Kidney-Metabolic Management

Aislinn Antrim, Managing Editor Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP
Prescription Drugs - Image credit: JJAVA | stock.adobe.com
June 12th 2025

Do We Really Pay More for Prescription Drugs in the United States?

Troy Trygstad, PharmD, PhD, MBA, Pharmacy Times Editor in Chief
Pharmacy students -- Image credit: DusanJelicic | stock.adobe.com
June 12th 2025

Addressing Pharmacy Deserts and Expanding the Pharmaceutical Workforce

Gillian McGovern, Associate Editor
Related Content
Advertisement
raw vegetables with blood glucose meter, syringe, lancet and stethoscope on desk, diabetes healthy diet concept - Image credit: neirfy | stock.adobe.com
June 12th 2025

Study: How Individual Carbohydrate Responses Reveal Metabolic Health and Potential Biomarkers

Kennedy Ferruggia, Assistant Editor
Pharmacy Focus: Navigating Seasonal Allergies
May 28th 2025

Pharmacy Focus: Navigating Seasonal Allergies

Luke Halpern, Assistant Editor Derek Webb, PharmD
Wooden blocks spelling biosimilars -- Image credit: lexiconimages | stock.adobe.com
June 12th 2025

Understanding Biologics and Biosimilars Amid an Evolving Treatment Landscape

Gillian McGovern, Associate Editor
Pharmacists Can Be At the Forefront of Cardio-Kidney-Metabolic Management
May 6th 2025

Pharmacists Can Be At the Forefront of Cardio-Kidney-Metabolic Management

Aislinn Antrim, Managing Editor Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP
Prescription Drugs - Image credit: JJAVA | stock.adobe.com
June 12th 2025

Do We Really Pay More for Prescription Drugs in the United States?

Troy Trygstad, PharmD, PhD, MBA, Pharmacy Times Editor in Chief
Pharmacy students -- Image credit: DusanJelicic | stock.adobe.com
June 12th 2025

Addressing Pharmacy Deserts and Expanding the Pharmaceutical Workforce

Gillian McGovern, Associate Editor
Consent Preferences
About Us
Clinical Forums
Advertise
Contact Us
Editorial Staff
Privacy Policy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.